Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(1):1; doi:10.1093/jnci/91.1.1
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 1, 1, January 6, 1999
© 1999 Oxford University Press

IN THIS ISSUE

Tamoxifen Resistance and Transforming Growth Factor-ß

Breast cancers can become resistant to treatment with the drug tamoxifen. Arteaga et al. (p. 46) have performed studies to uncover mechanisms that may play a role in this resistance. By use of a tamoxifen-resistant human breast cancer cell line, LCC2, and a related tamoxifen-sensitive line, LCC1, they showed that large amounts of transforming growth factor-ß2 were secreted by the resistant line but not by the sensitive line. They also showed that the growth of LCC2 tumors in nude mice could be inhibited by treatment with tamoxifen and neutralizing antibodies against . . . [Full Text of this Article]

Telomerase: Cellular Immortality and Its Reversal

Ferrets, ß-Carotene, and Tobacco Smoke

Vinorelbine, Quality of Life, and Advanced Non-Small-Cell Lung Cancer

Breast Cancer and Marital Stability

Predicting Sarcoma Aggressiveness


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?